Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy - Abstract

OBJECTIVE: To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer.

PATIENTS AND METHODS: Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed.

RESULTS: Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the "nadir prostate-specific antigen level" +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population.

CONCLUSION: In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.

Written by:
Yutkin V, Ahmed HU, Donaldson I, McCartan N, Siddiqui K, Emberton M, Chin JL.   Are you the author?
Division of Urology, Department of Surgery, University of Western Ontario, London, Ontario, Canada; Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Division of Surgery and Interventional Science, University College London, United Kingdom; Division of Urology, Department of Surgery, University of Western Ontario, London, Ontario, Canada.

Reference: Urology. 2014 Nov;84(5):1157-62.
doi: 10.1016/j.urology.2014.06.054


PubMed Abstract
PMID: 25443920

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe